Ximalaya Technology

Himalaya Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative oncology therapies, primarily for the Greater China market. The company was founded by Dr. Patrick Lu, the founder of Sirnaomics, and maintains a strategic partnership with Sirnaomics to leverage its drug development expertise and resources. Himalaya Therapeutics' lead candidate, HKP-1, is a recombinant L-asparaginase currently in Phase 1/2 clinical trials for the treatment of acute lymphoblastic leukemia. The company's pipeline also includes HKP-2, a peptide-based cancer vaccine licensed from BrightPath Biotherapeutics that targets multiple tumor-associated antigens in solid tumors. By combining internal R&D with strategic licensing of globally-sourced assets, Himalaya Therapeutics aims to address significant unmet medical needs in the oncology and hematology sectors.